News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase II
Ascendis Pharma A/S Announces Positive Top-line Results From A Phase 2 Pediatric Study Of Once-Weekly TransCon Growth Hormone For The Treatment Of Growth Hormone Deficiency 7/30/2015
Orgenesis Subsidiary MaSTherCell To Manufacture TxCell's Lead Product Ovasave For Multi-National Phase 2b Trial 7/30/2015
D-Pharm Ltd. Receives Final Report For Phase 2 Clinical Study Of DP-b99 In Acute High-Risk Pancreatitis Patients 7/30/2015
Isis Pharma (ISIS) Release: Positive Clinical Data From Volanesorsen Published In The New England Journal of Medicine 7/30/2015
GlaxoSmithKline (GSK) CEO Confident Investors Will Be Pleased With Pipeline on Nov. R&D Day 7/30/2015
Ascendis Pharma A/S To Report Top-Line Results From A Phase 2 Pediatric Study Of Once-Weekly Transcon Growth Hormone And Host Conference Call On Thursday, July 30, 2015 At 9:00 A.M. Eastern Time 7/30/2015
Galapagos (GLPG.BR)' Selective JAK1 Inhibitor Filgotinib Meets Key Efficacy Endpoints, Shows ACR70 Responses Up To 39%, And Maintains Safety Profile After 24 Weeks Of Treatment In DARWIN 1 Phase 2B Study 7/30/2015
Novavax, Inc. (NVAX) Announces Positive Data From Phase II Trial Of Quadrivalent Seasonal Influenza VLP 7/30/2015
Arena Pharmaceuticals, Inc. (ARNA) Initiates A Phase 2 Clinical Trial Of APD334, Its S1P1 Receptor Modulator For Autoimmune Diseases 7/29/2015
Viamet To Present At Infectious Diseases Society For Obstetrics And Gynecology Annual Meeting 7/29/2015
Qu Biologics Begins Phase 2 Clinical Trial In Ulcerative Colitis 7/29/2015
Viking Therapeutics (VKTX) To Conduct Phase II Trial Of VK2809 In Patients With Cholesterolemia And Fatty Liver Disease 7/29/2015
Corium International, Inc. Announces Positive Topline Results From Phase IIa Study Of Transdermal Microcor PTH In Post-Menopausal Women 7/29/2015
Progenics Pharmaceuticals, Inc. (PGNX) Announces Breakthrough Therapy Designation for Azedra in Pheochromocytoma And Paraganglioma 7/28/2015
Avraham Pharmaceuticals Ltd. Announces Successful Second Interim Results In Phase IIb Study Of Ladostigil For The Treatment Of Mild Cognitive Impairment 7/28/2015
GenSpera Phase II Abstract Accepted For Presentation At The Society Of Neuro-Oncology 20th Annual Scientific Meeting 7/28/2015
Kerastem Receives Conditional Approval From FDA For Alopecia Trial 7/28/2015
FDA Grants Breakthrough Therapy Designation To Eisai Inc. (ESALF.PK)'s Lenvatinib For The Potential Treatment Of Metastatic Renal Cell Carcinoma 7/28/2015
Cytori Therapeutics, Inc. (CYTX) Licensee Kerastem Receives Conditional Approval From FDA For Alopecia Trial 7/28/2015
Esperion Therapeutics (ESPR) Announces Positive Top-Line Phase 2 Results For ETC-1002 In Patients With Hypercholesterolemia And Hypertension 7/28/2015
Otonomy (OTIC) Initiates Phase II Clinical Trial For Auripro In Second Label Expansion Indication 7/28/2015
Embattled Vitae Pharma (VTAE) and Boehringer Ingelheim Relationship Takes Another Blow, Drops BACE Inhibitor Program for Alzheimer’s 7/27/2015
MonoSolRx LLC Announces Initiation Of Phase IIa Trial For Oral Insulin Film 7/27/2015
BioLineRx Ltd. Announces Top-Line Results From Bellerophon Therapeutics (BLPH)’s PRESERVATION I Clinical Trial For Bioabsorbable Cardiac Matrix (BL-1040) 7/27/2015
MediciNova, Inc. Announces FDA Approval Of The Second Phase II Protocol For MN-001 In NASH Which Targets NASH Patients With Hypertriglyceridemia 7/27/2015
Bavarian Nordic (BAVA.CO) Announces Initiation Of NCI-Sponsored Phase 2 Study Of PROSTVAC In Patients With Localized Prostate Cancer 7/24/2015
Vista Partners Initiates Coverage On Immune Pharmaceuticals, Inc. (NasdaqCM: IMNP); $6.00 Price Target 7/24/2015
AcelRx (ACRX) Announces Positive CHMP Opinion For Zalviso In The Management Of Acute Moderate-To-Severe Post-Operative Pain In Adult Patients 7/24/2015
Janssen Therapeutics Submits Supplemental New Drug Application To U.S. FDA For All-Oral, Once-Daily OLYSIO (Simeprevir) In Combination With Sofosbuvir 7/24/2015
Recro Pharma (REPH) Announces Additional Information For Phase II Clinical Trial Of Dex-IN 7/24/2015
Heron (HRTX) Initiates Second Phase II Clinical Trial Of HTX-011 For The Treatment Of Post-Operative Pain 7/23/2015
Cara Therapeutics, Inc. (CARA) Soars 35% on Positive Phase II Uremic Pruritus Data 7/23/2015
Inotek Pharmaceuticals Corporation Announces Positive End-Of-Phase II Meeting With FDA And Phase III Development Strategy For Trabodenoson, A Novel Treatment For Glaucoma 7/23/2015
NeuralStem Inc. Release: US District Court Rules In Favor Of Neuralstem In Patent Infringement Case 7/23/2015
FDA Grants "Fast Track" To Omeros Corporation (OMER)' Complement Inhibitor OMS721 For aHUS 7/23/2015
Isis Pharma (ISIS) Release: Positive Clinical Data From Lp(a) Lowering Drug ISIS-APO(a) Rx Published In The Lancet 7/23/2015
Mesoblast (MSB.AX) Release: Type 2 Diabetes Trial Results Published In Diabetes Care 7/23/2015
SCYNEXIS, Inc. (SCYX) To Focus On SCY-078 Development 7/23/2015
Inovio Pharmaceuticals (INO) And European Organization for Research and Treatment of Cancer To Collaborate On Large Phase II Cervical Cancer Trial 7/23/2015
New Data Presented At The 2015 Alzheimer's Association International Conference Include Three Reports Of Clinical Trials Targeting Cognition, Agitation, Patient Management 7/22/2015
AstraZeneca PLC (AZN) Commences AZD9412 Phase II Trial In Severe Asthma 7/22/2015
Bristol-Myers Squibb (BMY) Release: Second-Generation Investigational HIV-1 Maturation Inhibitor Demonstrates Positive New Phase IIa Results, Supporting Continued Development 7/22/2015
Axovant (AXON)'s RVT-101 Phase 2b Completer Analysis Demonstrates Statistically Significant Benefits In Cognition And Function Through 48 Weeks 7/22/2015
Anavex (AVXL) Presents Positive Initial Phase IIa Study Data With ANAVEX 2-73 Showing Early Evidence Of Improving Cognition In Patients With Alzheimer’s Disease At AAIC 2015 7/22/2015
Bristol-Myers Squibb (BMY) Nails FDA Breakthrough Designation for Next-Gen HIV-1 Attachment Inhibitor 7/21/2015
Therabron Therapeutics Reaches 50 Percent Enrollment In Phase 2 Clinical Trial For Lead Pediatric Respiratory Critical Care Program 7/21/2015
Isis Pharma (ISIS) Initiates Clinical Study Of ISIS-HTT Rx In Patients With Huntington's Disease 7/21/2015
MediciNova, Inc. Announces Update On Development Plans For MN-001 In IPF 7/21/2015
TetraLogic Pharmaceuticals (TLOG) Provides Update On Hepatitis B Clinical Program 7/21/2015
Adaptimmune’s NY-ESO-1 TCR-Engineered T-Cells Demonstrate Durable Persistence, Clinical Activity And Tolerability In Clinical Study In Multiple Myeloma Patients 7/20/2015
InnaVirVax Presents Highly Encouraging Results Of Its First Clinical Study On VAC-3S Immunotherapy For HIV 7/20/2015
ERYtech Pharma Announces Positive Safety Review For ERY-ASP In Its Phase II Study In Pancreatic Cancer 7/20/2015
Cell MedX Corp. (CMXC) Advances Development Timeline 7/20/2015
aTyr Pharma Announces Transitions In Clinical Development & Operations 7/20/2015
CASI Pharmaceuticals  (CASI) Announces Availabilty Of Anti-Cancer Drug ZEVALIN In Hong Kong For Non-Hodgkin's Lymphoma 7/20/2015
The Lancet Infectious Diseases Journal Publishes Results Of Phase II Study Of Lonafarnib In Hepatitis Delta Virus (HDV) Infected Patients 7/20/2015
Delcath Systems (DCTH) Receives Orphan Drug Designation From FDA For Melphalan To Treat Cholangiocarcinoma 7/20/2015
Amarantus BioSciences, Inc. Announces First Patient Dosed In Eltoprazine Phase IIb Study For Treatment Of Parkinson's Disease Levodopa-Induced Dyskinesia 7/20/2015
StemCells (STEM) Transplants First Patient In Phase II Clinical Trial For Dry Age-Related Macular Degeneration 7/20/2015
BioMarin (BMRN) Provides Program Update For Talazoparib In Metastatic Breast Cancer 7/20/2015
Amgen (AMGN) Lauds Positive Phase II Data for Leukemia Drug Blincyto 7/17/2015
RegeneRx Biopharmaceuticals, Inc. (RGRX) Korean Licensee Receives Government Approval To Conduct Phase 2b/3 Clinical Trial In Patients With Dry Eye Syndrome 7/17/2015
Recro Pharma (REPH) Announces Positive Top-Line Results For Phase II Clinical Trial Of Dex-IN 7/17/2015
Baxalta’s BAX 855 Pivotal Data Published In Blood Shows Potential To Provide Strong Bleed Prevention With Twice Weekly Dosing For Patients With Hemophilia A 7/16/2015
Zogenix (ZGNX) and FDA Delay Two Rare Epilepsy Trials by Three Months 7/15/2015
Ascenion GmbH Release: New Tuberculosis Vaccine Reaches Further Clinical Development Milestone 7/15/2015
AB Science (AB.PA) Announces Initiation Of An Adaptive Design Phase II/III Study With Masitinib In Patients With Refractory Metastatic Ovarian Cancer 7/15/2015
Aerpio Announces Positive Results Of A Phase IIa Study Of AKB-9778 In Diabetic Macular Edema: The TIME-2 Trial 7/15/2015
OptiNose AS Announces Positive Early Phase Clinical Trial With OPN-300, An Investigational Product In Development For Treatment Of Autism Spectrum Disorders 7/15/2015
FORUM Pharma Announces Publication Of Encenicline Phase II Clinical Trial Results For Cognitive Impairment In Schizophrenia 7/15/2015
Cerenis Therapeutics, Inc. Announces The Results Of The LOCATION Study 7/15/2015
Bavarian Nordic (BAVA.CO) Announces That The Oxford Vaccines Group Has Initiated A Phase II Study Of The Ebola Prime-Boost Vaccine Regimen Combining MVA-BN Filo And Janssen's Advac Technology 7/15/2015
Medgenics, Inc. Announces First Patient Enrolled In U.S.-Based Phase II Clinical Trial Of TARGT-EPO For Treatment Of Anemia In ESRD Patients Undergoing Peritoneal Dialysis 7/15/2015
Mesoblast (MSB.AX) Release: Congestive Heart Failure Phase Trial Results Published In Circulation Research 7/15/2015
Genentech (RHHBY)’s Breakthrough Atezolizumab Joins Club of Successful Anti-PD-L1 Drugs, Shrinks Tumors in Bladder Cancer 7/14/2015
Enteris Biopharma Oral Formulation Progresses Into Phase 2 Study With Cara Therapeutics, Inc. (CARA)' CR845 7/14/2015
ErgoMed’s Co-Development Partner Ferrer Initiates Phase IIa Study Of Lorediplon In Patients With Insomnia 7/14/2015
Celator Pharmaceuticals, Inc. Announces Start Of Clinical Study Of CPX-351 In Acute Myeloid Leukemia Patients At High Risk For Induction Mortality 7/14/2015
Oncoceutics Announces Completion Of ONC201 First-in-Man Study 7/13/2015
Corbus Announces Dosing Of First Patient In Phase II Clinical Trial Of Resunab For The Treatment Of Dermatomyositis 7/13/2015
pSivida (PSDV) Announces Positive Top Line Results From Investigator-Sponsored Phase II Study Of Medidur For Uveitis 7/13/2015
Allegro Ophthalmics LLC Announces Positive Topline Results From Phase II Trial Evaluating Luminate® In Patients With Vitreomacular Traction Or Vitreomacular Adhesion 7/13/2015
C3 Jian, Inc. Completes Second Phase II Clinical Trial Of Anti-Cavity Drug 7/13/2015
In A Pivotal Study, Genentech (RHHBY)’s Investigational Immunotherapy Atezolizumab Shrank Tumors In People With A Specific Type Of Bladder Cancer 7/13/2015
Ohr Pharma (OHRP) Announces Positive Results Of A Phase II Clinical Study For OHR-102 In Retinal Vein Occlusion 7/13/2015
Epizyme (EPZM) Doses First Patient In Five-Arm Phase 2 Study For First-In-Class EZH2 Inhibitor Tazemetostat (EPZ-6438) In Relapsed Or Refractory Non-Hodgkin Lymphoma 7/10/2015
BIO2015 EXCLUSIVE: BioSpace (DHX)’s Insider Profile of Neovacs SA 7/9/2015
Regen BioPharma Reports Successful Dosing Of HemaXellerate In FDA-Requested GLP Animal Study 7/9/2015
DelMar Pharmaceuticals To Present Updated Phase I/II Clinical Data On Val-083 In The Treatment Of Refractory Glioblastoma Multiforme At GBM2015: 2nd International Symposium On Clinical And Basic Investigation In Glioblastoma 7/9/2015
Janssen Research & Development Release: Phase 2b Findings Published In The New England Journal Of Medicine Demonstrate Significant Efficacy Of Guselkumab In Treatment Of Moderate To Severe Plaque Psoriasis 7/9/2015
Positive Data Announced In Phase IIb Clinical Trial Of Cystic Fibrosis Gene Therapy Manufactured By VGXI, Inc. 7/9/2015
Scancell Patient Recruitment Completed For SCIB1 Phase 1/2 Clinical Trial 7/9/2015
Seattle Genetics (SGEN) Initiates Clinical Trial Of ADCETRIS (Brentuximab Vedotin) In Systemic Lupus Erythematosus, A Chronic Autoimmune Disease 7/9/2015
Ultragenyx Pharmaceuticals (RARE) Releases Positive Interim 40-Week Bone Treatment Data From Ongoing Pediatric Phase II Study Of KRN23 In X-Linked Hypophosphatemia 7/9/2015
EXCLUSIVE: DNAnexus, Stanford University Genomic Catalog Will Accelerate Science in the Field, Says CEO 7/8/2015
Trophogen, Inc. Awarded $756,000 For Second Year Of Phase 2 NIH/NCI Fast Track SBIR Grant For Development Of Novel Human VEGF Analogs For Targeted Imaging Of Undifferentiated Thyroid Cancer 7/8/2015
Admedus Release: Cardiocel Shows No Evidence Of Calcification After 7 Years In Long Term Follow-Up To Phase II Trial 7/8/2015
Summit Therapeutics Receives FDA Fast Track Designation For Novel Antibiotic SMT19969 In The Treatment Of C. Difficile Infection 7/8/2015
Independent Data Safety Monitoring Board Recommends Continuation Per Protocol Of Genticel's Phase II Clinical Trial Of GTL001 (Procervix), Company's First-In-Class HPV Therapeutic Vaccine Candidate 7/8/2015
Aridis Pharmaceuticals Expands Phase 2a Trial Into The U.S. For Monoclonal Antibody AR-301 For The Treatment Of Acute Pneumonia 7/8/2015
Independent Data Safety Monitoring Board Recommends Continuation, Per Protocol, Of Genticel’s Phase 2 Clinical Trial Of GTL001 (Procervix), Company’s First-In-Class HPV Therapeutic Vaccine Candidate 7/7/2015
pSivida (PSDV) Announces Top-Line Results From Investigator-Sponsored Phase II Study Of Medidur For Uveitis To Be Reported Next Week 7/7/2015
Pfizer (PFE) Begins Phase IIb Study Of Its Investigational Multi-Antigen Staphylococcus Aureus Vaccine In Adults Undergoing Elective Spinal Fusion Surgery 7/7/2015
Thrasos Completes Enrollment Of Phase II THR-184 Clinical Study For Acute Kidney Injury 7/7/2015
Oncolytics Biotech Inc. (ONC.TO) Collaborators Present Final Data From REO 017 Clinical Study In Pancreatic Cancer 7/7/2015
SteadyMed (STDY) Completes Program Of Human Factors Studies Validating Usability Of Trevyent 7/7/2015
XBiotech USA (XBIT) Announces Publication Of Clinical Results Supporting Its True Human Antibody Therapy For Type 2 Diabetes Mellitus 7/7/2015
CureVac Announces Phase I/IIa Clinical Study Data Of Its mRNA Cancer Immunotherapy In Prostate Cancer Published In The Journal For Immunotherapy Of Cancer 7/7/2015
Ansun BioPharma Publishes Effects of FluDase On Drug Resistant Flu 7/7/2015
Kamada Ltd. (KMDA) Announces Publication In Pediatric Diabetes 7/6/2015
ArQule, Inc. (ARQL) Announces Interim Phase II Study Results For Tivantinib In Combination With Cetuximab In Patients With MET-High, KRAS Wild Type Colorectal Cancer Presented At ESMO World Congress On Gastrointestinal Cancer 2015 7/6/2015
Celsion Corporation (CLSN) Announces Continuing Positive Data From Its Phase 2 DIGNITY Study In Breast Cancer 7/6/2015
Array BioPharma, Inc. (ARRY) Release: Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 7/6/2015
Marinus Pharmaceuticals (MRNS) Release: Published Data Support Scientific Basis For Ganaxolone Use In PCDH19 Female Epilepsy 7/6/2015
Akcea Therapeutics Receives Orphan Drug Designation From The US FDA For Volanesorsen (ISIS-APOCIII Rx) For The Treatment Of Familial Chylomicronemia Syndrome 7/6/2015
Celtaxsys, Inc. Gains FDA Clearance For Landmark Phase 2 Trial Of Anti-Inflammatory Treatment For Cystic Fibrosis (CF) 7/6/2015
Evotec AG (EVTG.F), Roche (RHHBY)'s Alzheimer's Hopeful Fails Another Trial 7/2/2015
EXCLUSIVE: Pediatric Patients Could Benefit Most From New Oncoceutics Cancer Drug, Says Exec 7/2/2015
Cyclacel Pharmaceuticals, Inc. (CYCC) Release: First Patient Dosed In IST Of CDK Inhibitor Seliciclib In Cushing's Disease, A Serious Endocrine Disorder 7/2/2015
Avexxin Completes Phase I/IIA Study In Psoriasis And Achieves Proof-Of-Concept In Man With Its Compound AVX001 In A Topical Formulation 7/2/2015
Avineuro Completed Phase II Clinical Study Of AVN-211, A Selective 5-HT6 Receptor Antagonist 7/1/2015
VistaGen Therapeutics, Inc. Receives FDA And NIH Clearance To Initiate NIH-Funded Phase 2 Study Of Orally Active AV-101 In Major Depressive Disorder 7/1/2015
Teva (TEVA) And Xenon Pharmaceuticals Inc. Provide Update On TV-45070 Phase IIb Study In Osteoarthritis Pain 7/1/2015
TetraLogic Pharmaceuticals (TLOG) Announces Update On MDS Clinical Program 7/1/2015
Pharma Two B Ltd. Announces Positive Results In Its Phase Ilb Pivotal Clinical Study Of P2B001 For The Treatment Of Early Stage Parkinson's Disease 6/30/2015
BiondVax Pharmaceuticals Presents BVX-006 Preliminary Phase II Results: The Universal Flu Vaccine At Higher Doses Is Safe And Improves Immunogenicity In Older Adults 6/30/2015
Oramed Pharmaceuticals Inc. (ORMP) Enrolls First Patient In Its Phase Ilb Oral Insulin Study 6/30/2015
Oramed Pharmaceuticals Inc. (ORMP) Submits Protocol To U.S. FDA For Its Phase Ilb Oral Insulin Study 6/30/2015
Anavex (AVXL) To Present Initial Clinical Data From The Phase IIa Clinical Trial Of ANAVEX 2-73 At The Alzheimer’s Association International Conference (AAIC) 6/30/2015
Replicel Life Sciences Enrolls First Participant In Phase 1/2 Clinical Trial Of RCT-01 For Chronic Achilles Tendinosis 6/30/2015
Vitae Pharma (VTAE) Announces Top-Line Results From Metformin Arm of Ongoing Phase II Clinical Trial of BI187004/VTP-34072 in Overweight Type 2 Diabetics 6/29/2015
Vitae Pharma (VTAE)’ Diabetes Drug Fails Mid-Stage Trial, the Second Drug in Less Than Six Months to Fail 6/29/2015
Invion Limited Completes Dosing In Key Phase II Clinical Trial Of Oral INV102 (Nadolol) In Smoking Cessation 6/29/2015
IND For Phase 1b/2 Ovarian Cancer Trial Transferred To Prescient Therapeutics 6/29/2015
BioBlast Pharma (ORPN) Receives Orphan Drug Designation From The European Commission (EC) For Cabaletta For The Treatment Of Spinocerebellar Ataxia (SCA) 6/29/2015
Aduro Biotech (ADRO) Announces Immunotherapy Regimen Successfully Passes Futility Analysis In Phase IIb ECLIPSE Trial In Metastatic Pancreatic Cancer 6/29/2015
Galectin Therapeutics Initiates Enrollment For GR-MD-02 Phase II Clinical Trial In NASH With Cirrhosis 6/29/2015
Aratana Therapeutics (PETX) Announces Positive Pivotal Results For AT-002 6/29/2015
Synthetic Biologics, Inc. (SYN)' Initiates SYN-010 Phase 2 Clinical Trial To Treat Irritable Bowel Syndrome With Constipation (IBS-C) 6/29/2015
Immune Pharmaceuticals, Inc. Initiates Phase II Clinical Trials With Bertilimumab In Ulcerative Colitis And Bullous Pemphigoid 6/26/2015
PledPharma Presents Additional Results From A Phase IIb Study With Pledox At The Scientific Conference MASCC 6/26/2015
StemCells (STEM) Reports Top Line Results For Its Phase I/II Study In Dry Age Related Macular Degeneration 6/26/2015
Aquinox (AQXP)’s Bladder Pain Drug Fails to Meet Statistical Endpoint in Phase II Trial 6/25/2015
Hemostemix Enrolls Fifth Participant At Vancouver General Hospital In International Phase-2 Clinical Trial For Critical Limb Ischemia 6/25/2015
Derma Sciences, Inc. (DSCI) Announces Publication In Advances In Wound Care 6/25/2015
Conatus Pharma Announces Initial Baseline Data From Phase 2b POLT-HCV-SVR Clinical Trial Of Emricasan Confirming Activity Of Relevant Mechanisms And Opportunity For Histological Improvement 6/25/2015
Alcobra (ADHD)’s Fragile X Syndrome Drug Fails During Mid-Stage Trial 6/24/2015
Vical  (VICL) Herpes Vaccine Clinical Trial Disappoints with "Confounding Results" 6/24/2015
Evoke Pharma, Inc. Announces Publication of Clinical Data Demonstrating EVK-001 Significantly Improves Symptoms in Women With Diabetic Gastroparesis 6/24/2015
Spectrum Pharmaceuticals, Inc. (SPPI) Announces Publication Of Beleodaq Data Selected As A Rapid Communication In The Journal Of Clinical Oncology 6/24/2015
Acorda Therapeutics (ACOR) Data On Inhaled Levodopa Therapy CVT-301 Recognized In Blue Ribbon Highlights Session At International Congress Of Parkinson's Disease And Movement Disorders 6/24/2015
Baxalta Reports Continued Progress On Phase 1/2 Clinical Trial Of BAX335, Investigational Gene Therapy Treatment For Hemophilia B 6/24/2015
Vaccinex, Inc. Announces The Initiation Of A Phase 2 Clinical Trial Of Its Investigational VX15/2503 Antibody In Huntington's Disease (The SIGNAL Trial) 6/24/2015
Vanda Pharmaceuticals, Inc. (VNDA) Announces Positive Results From The Relapse Prevention Study In Patients With Schizophrenia (REPRIEVE) Demonstrating The Long-Term Maintenance Effects Of Fanapt (iloperidone) 6/24/2015
Transition Therapeutics Inc. (TTH.TO) Announces Results Of Clinical Study Of ELND005 In Agitation And Aggression In Patients With Alzheimer's Disease 6/24/2015
Helix Biopharma (TSX:HBP) Initiates Enrollment For Thirteenth Cohort In Polish Phase I/II Clinical Study Of Its Lung Cancer Drug Candidate L-DOS47 6/23/2015
ObsEva Announces Recruitment Of The First Patient In TERM Phase 2 Study 6/23/2015
Cara Therapeutics, Inc. (CARA) Completes Enrollment Of Phase 2 Trial Of I.V. CR845 In Uremic Pruritus 6/23/2015
Zosano Pharma, Inc. Completes Enrollment In Phase 2 Trial For ZP-Glucagon, Its Microneedle Patch For Treatment Of Severe Hypoglycemia 6/23/2015
BioMarin (BMRN) Surging on Impressive Phase II Dwarfism Data 6/22/2015
AOBiome Announces Start Of First Clinical Trial with Ammonia Oxidizing Bacteria-Based Therapeutic For Treatment Of Acne 6/22/2015
Investigator-Sponsored Trial Evaluating Biothera’s Imprime PGG In Relapsed Indolent Non-Hodgkin Lymphoma 6/22/2015
Isis Pharma (ISIS) Reports Data From ISIS-SMN Rx In Children With Spinal Muscular Atrophy 6/22/2015
Vaxil BioTherapeutics's Lead Product Immucin Has Been Granted An Orphan Drug Designation By The FDA For The Treatment Of Multiple Myeloma 6/22/2015
Amgen (AMGN) Presents Open-Label Extension Data From Ongoing Phase 2 Study Of AMG 334 In The Prevention Of Episodic Migraine 6/19/2015
Burzynski Research Institute Announces Publication Of Phase II Results In Adults With Recurrent Anaplastic Astrocytoma 6/19/2015
Tekmira (TKMR) Provides Update On TKM-Ebola-Guinea 6/19/2015
Bay Area's Aimmune Wins FDA Breakthrough Therapy Designation for Allergy Drug 6/18/2015
Analysts Question Avalanche Biotech (AAVL) Clinical Data, Could Jeopardize Regeneron (REGN) Deal 6/18/2015
bluebird bio (BLUE) Surges as Pioneering Sickle Cell Gene Therapy Working for 13-Year-Old French Boy 6/18/2015
TG Therapeutics, Inc. (MHA) Release: Updated Results From Phase II Clinical Trial Of TG-1101 (Ublituximab) In Combination With Ibrutinib Confirms Robust Clinical Activity With A Favorable Safety Profile In Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL) 6/18/2015
Akashi Therapeutics Reports Positive Clinical Data On HT-100 In Patients With Duchenne Muscular Dystrophy 6/18/2015
Galapagos (GLPG.BR) Completes Recruitment For ORIGIN Phase 2 Trial With GLPG1205 In Ulcerative Colitis Patients 6/18/2015
StemCells (STEM)'s Phase II Pathway Study For Cervical Spinal Cord Injury Approved By Health Canada 6/18/2015
Eli Lilly (LLY)'s Investigational Medicine For Prevention Of Migraine Met Primary Endpoint In A Phase 2b Study 6/17/2015
FDA's Office Of Orphan Products Development Issues Grant Supporting GenSpera Glioblastoma Study 6/17/2015
Nordic Nanovector: Updated Results Of Ongoing Phase 1/2 Study With Betalutin In Relapsed CD37+ Non-Hodgkin Lymphoma Patients 6/17/2015
Arrowhead Research Corporation (ARWR) Receives Regulatory Clearance To Begin Additional Phase 2b Studies Of Hepatitis B Candidate ARC-520 6/17/2015
Astellas Pharma Inc. (ALPMY) And Medivation, Inc. (MDVN) Announce Enrollment Of The First Patients In Advanced Prostate Cancer Outcomes Registry 6/17/2015
Phase II Clinical Trial Featuring 22nd Century Group, Inc.'s Very Low Nicotine Tobacco Accepted For Publication 6/17/2015
Strategic Science & Technologies Initiates Phase II Study To Evaluate Topical Sildenafil In Men With Erectile Dysfunction 6/17/2015
BiondVax Pharmaceuticals Announces FDA Acceptance Of IND Application For Its Investigational Universal Flu Vaccine 6/17/2015
Eli Lilly (LLY) Hits 14-Year High as Investors Await Alzheimer's Data 6/16/2015
Acetylon Pharmaceuticals Presented Positive Preliminary Data From Phase 1b/2 Trial Of Ricolinostat In Combination With Pomalyst As Potential Oral Treatment For Patients With Multiple Myeloma 6/16/2015
Clearside Biomedical Announces Favorable End-of-Phase 2 Review With The FDA 6/16/2015
Pulmatrix Announces First Inhaled Anti-fungal Therapy For Cystic Fibrosis 6/16/2015
Avalanche Biotech (AAVL) Announces Positive Top-Line Phase IIa Results For AVA-101 In Wet Age-Related Macular Degeneration 6/16/2015
Teva (TEVA) Advances Pipeline Of Movement Disorder Assets With Announcement Of Positive Top-Line Data From The First Pivotal Study Of Investigational Treatment For Patients With Tardive Dyskinesia 6/16/2015
Heron (HRTX) Initiates Phase II Clinical Trial Of HTX-011 For The Treatment Of Post-Operative Pain 6/16/2015
Akaal Pharma Receives Approval To Initiate Phase II Clinical Trial For The Topical Treatment Of Psoriasis 6/16/2015
TONIX Pharmaceuticals, Inc. (TNXP) Initiates Phase II Clinical Study Of TNX-201 In Episodic Tension-Type Headache 6/16/2015
Juventas Therapeutics, Inc. Granted FDA Fast Track Designation And Phase 2b Protocol Allowance For Novel Heart Failure Gene Therapy 6/16/2015
Heat Biologics Announces Development Of Compact, A Next Generation Combination Immunotherapy Platform 6/15/2015
Adamas Pharmaceuticals (ADMS) Announces Additional Findings From Its Phase II/III Trial Of ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) Associated With Parkinson's Disease 6/15/2015
Celgene (CELG) Release: Results From Analyses Of Revlimid MCL-002 (SPRINT) Study Presented At European Hematology Association 6/15/2015
Cytori Therapeutics, Inc. (CYTX) Completes Enrollment In US Phase IIb Osteoarthritis Trial 6/15/2015
XBiotech USA (XBIT) Announces Publication Of Phase II Clinical Results For Its True Human Antibody Mabp1 For Treating Acne Vulgaris 6/15/2015
CTI BioPharma Release: Tosedostat In Combination With Low Dose Cytarabine Achieves Primary Endpoint In Phase 2 Study In Elderly Patients With AML 6/15/2015
BioLineRx Ltd. Presents Positive Safety And Efficacy Results For Novel Stem-Cell Mobilization Treatment At European Hematology Association Conference 6/15/2015
Galena Biopharma  (GALE) Presents GALE-401 (Anagrelide Controlled Release) Phase II Data At The European Hematology Association 20th Congress 6/15/2015



//-->